Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer

Phase 2 Unknown 130 enrolled Xiaohua Wu MD

RandomizedParallel-groupOpen-labelTreatment

Summary

Ovarian cancer was mostly diagnosed at late stage (III/IV) with high rate of recurrence after first line of therapy by optimal cytoreductive sugery and 6-8cycle of TP chemotherapy. We developed an adjuvant chemotherapy of "three steps" (ACTS). It is adding CTX+VP-16(second step)6cycle and CTX+CBP(third steps) to firstline chemotherapy (first step). The aim of this study is to verify the effectivity and safety of ACTS.

Timeline

Start: 2015-11
Primary completion: 2023-11
Completion: 2023-11

Publications

Zheng Z, Wang H, Yang H, Tang J, Cheng X, Zhang M, Ren Y, Chen X, Ju X, Xu L, Wu X. Efficacy of Maintenance Therapy With Adjuvant Chemotherapy of Three Steps in Patients Newly Diagnosed With Advanced Ovarian Cancer: A Phase II Randomised Clinical Trial. BJOG. 2025 Jun;132(Suppl 4):52-61. doi: 10.1111/1471-0528.18178. Epub 2025 Apr 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	—	Intravenous
Subject	Cyclophosphamide	Other / unclassified	250 mg/m2	Intravenous
Subject	Cyclophosphamide	Other / unclassified	400 mg	Intravenous
Subject	Cyclophosphamide	Other / unclassified	400 mg/m2	Intravenous
Subject	Cyclophosphamide	Other / unclassified	600 mg	Intravenous
Subject	Etoposide	Small molecule	70 mg/m2	Intravenous
Subject	Etoposide	Small molecule	100 mg	Intravenous

Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer

Summary

Timeline

Publications

Drugs

Indications